Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$168.59 USD

168.59
4,377,458

+2.03 (1.22%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $168.50 -0.09 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie Down on Humira Patent Loss: Is More Damage in Store?

by Zacks Equity Research

AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),

    Sheraz Mian headshot

    New Stock Research Reports for Boeing, AbbVie and UnitedHealth

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV) and UnitedHealth (UNH).

      Celgene's (CELG) Revlimid Looks Solid on Label Expansion

      by Zacks Equity Research

      Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.

        AbbVie and J&J Present Positive Imbruvica Leukemia Data

        by Zacks Equity Research

        AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).

          Infinity (INFI) Reports Narrower-than-Expected Loss in Q1

          by Zacks Equity Research

          Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.

            Arpita Dutt headshot

            Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

            by Arpita Dutt

            Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.

              Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

              by Zacks Equity Research

              Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

                AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y

                by Zacks Equity Research

                AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.

                  AbbVie (ABBV) Beats Earnings and Revenue in Q1

                  by Zacks Equity Research

                  AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.

                    Tracey Ryniec headshot

                    5 Fantastic Earnings Charts

                    by Tracey Ryniec

                    Tracey brings you the companies with the best earnings charts each week.

                      Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

                      by Zacks Equity Research

                      Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

                        Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

                        by Zacks Equity Research

                        Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

                          Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong

                          by Zacks Equity Research

                          Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.

                            AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                            by Zacks Equity Research

                            AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                              What's in Store for AbbVie (ABBV) this Earnings Season?

                              by Zacks Equity Research

                              AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

                                What's in Store for Biogen (BIIB) this Earnings Season?

                                by Zacks Equity Research

                                Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

                                  AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

                                  by Zacks Equity Research

                                  AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.

                                    Repros' Proellex Continues to be Under Partial Clinical Hold

                                    by Zacks Equity Research

                                    Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver

                                      Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                                      by Zacks Equity Research

                                      Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                                        AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                                        by Zacks Equity Research

                                        AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

                                          AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

                                          by Zacks Equity Research

                                          AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

                                            AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

                                            by Zacks Equity Research

                                            AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

                                              Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

                                              by Zacks Equity Research

                                              Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

                                                Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

                                                by Zacks Equity Research

                                                Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

                                                  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

                                                  by Zacks Equity Research

                                                  Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate